BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 12975638)

  • 1. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
    Padwal R; Li SK; Lau DC
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1437-46. PubMed ID: 12975638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
    Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Lau J
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004096. PubMed ID: 15674929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term pharmacotherapy for obesity and overweight: updated meta-analysis.
    Rucker D; Padwal R; Li SK; Curioni C; Lau DC
    BMJ; 2007 Dec; 335(7631):1194-9. PubMed ID: 18006966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
    Viner RM; Hsia Y; Tomsic T; Wong IC
    Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A; Horvath K; Jeitler K; Berghold A; Stich AK; Matyas E; Pignitter N; Siering U
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007654. PubMed ID: 19588440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Siering U; Semlitsch T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007654. PubMed ID: 23543553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
    Ara R; Blake L; Gray L; Hernández M; Crowther M; Dunkley A; Warren F; Jackson R; Rees A; Stevenson M; Abrams K; Cooper N; Davies M; Khunti K; Sutton A
    Health Technol Assess; 2012; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.
    Neovius M; Johansson K; Rössner S
    Obes Rev; 2008 Sep; 9(5):420-7. PubMed ID: 18208467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
    O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
    Health Technol Assess; 2001; 5(18):1-81. PubMed ID: 11399238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.